Timothy R. Koscik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Timothy R. Koscik has a total of 304 co-authors. Here are the top co-authors by number of shared publications:
- Ellen van der Plas
Division of Pediatric Hematology/Oncology Department of Pediatrics University of Arkansas for Medical Sciences Little Rock Arkansas USA
10 shared publications - Peg Nopoulos
Department of Psychiatry Carver College of Medicine at the University of Iowa Iowa City Iowa USA
10 shared publications - Daniel Tranel
Department of Neurology, Roy J. and Lucile A. Carver College of Medicine, University of Iowa
8 shared publications - Vincent A. Magnotta
University of Iowa
7 shared publications - Amy Lynn Conrad
University of Iowa College of Medicine, Iowa City, IA, USA
5 shared publications - Sarah A. Cumming
School of Molecular Biosciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
5 shared publications
Latest Publications
- Open Access
Feasibility of Non-Sedated Multispectral Neuroimaging in Newly Diagnosed Children with Leukemia
Introduction: Children with acute lymphoblastic leukemia (ALL) require neurotoxic treatment during critical periods of brain development. Multispectral magnetic resonance imaging (MRI) offers opportunities to characterize the impact of chemotherapy on the developing brain, but this has been constrained by concerns regarding feasibility of obtaining quality MRIs from these critically ill children at a young age. Our goal is to demonstrate a framework for improving the feasibility of non-sedated, multispectral MRI in newly diagnosed ALL patients. Methods: Participants were enrolled from August 2023 through February 2026, and included newly diagnosed ALL patients and controls recruited from the community ages 3-10 years old. Participants completed a series of three non-sedated MRI without contrast on a 3T scanner over 12 months. Sequences included anatomical T1-weighted and QALAS sequences for quantitative mapping, diffusion weighted MRI (DWI), MR Spectroscopy (MRS), and resting-state functional MRI (rs-fMRI). A sequence was considered complete if data quality was sufficient for successful image processing. Mixed-effects logistic regression models were used determine if group and study visit were associated with MRI success rates across sequences. Results: The sample included 17 ALL patients and 30 controls, who contributed to 38 and 75 observations, respectively. Of 113 attempted scans, 105 had ≥1 sequence completed (93%). Across assessments, ALL patients were less likely to complete a scan (31 of 38 attempts; raw rate: 82%) relative to controls (73 of 75; raw rate: 96%; model-estimated difference=-14.1%, 95%CI=-27.1%; -1.1%, p=0.033). Baseline success rate was 65% (11 of 17) for ALL patients and 93% (28 of 30) for controls (model-estimated difference=-26.8%, 95%CI=-52.7%; -0.9%, p=0.42); however, nearly all T1w scans in ALL patients were successful at follow-up visits (20 of 21; 95%), with no significant differences between groups (model-estimated difference at follow-up 1=-2.1%, 95%CI=-11.7%; 7.6%; model-estimated difference at follow-up 2=-8.3%, 95%CI=-26.3%; 9.6%). A similar pattern was observed for DWI, MRS and rs-fMRI sequences with relatively high completion rates at follow-up assessments. Discussion: Non-sedated multispectral MRI is feasible in young children with newly diagnosed ALL, particularly with repeated visits and structured behavioral preparation. These results highlight opportunities to capture the scope and depth of neurodevelopmental changes concurrent with ALL treatment.
Open AccessFeasibility of Non-Sedated Multispectral Neuroimaging in Newly Diagnosed Children with Leukemia
Introduction: Children with acute lymphoblastic leukemia (ALL) require neurotoxic treatment during critical periods of brain development. Multispectral magnetic resonance imaging (MRI) offers opportunities to characterize the impact of chemotherapy on the developing brain, but this has been constrained by concerns regarding feasibility of obtaining quality MRIs from these critically ill children at a young age. Our goal is to demonstrate a framework for improving the feasibility of non-sedated, multispectral MRI in newly diagnosed ALL patients. Methods: Participants were enrolled from August 2023 through February 2026, and included newly diagnosed ALL patients and controls recruited from the community ages 3-10 years old. Participants completed a series of three non-sedated MRI without contrast on a 3T scanner over 12 months. Sequences included anatomical T1-weighted and QALAS sequences for quantitative mapping, diffusion weighted MRI (DWI), MR Spectroscopy (MRS), and resting-state functional MRI (rs-fMRI). A sequence was considered complete if data quality was sufficient for successful image processing. Mixed-effects logistic regression models were used determine if group and study visit were associated with MRI success rates across sequences. Results: The sample included 17 ALL patients and 30 controls, who contributed to 38 and 75 observations, respectively. Of 113 attempted scans, 105 had ≥1 sequence completed (93%). Across assessments, ALL patients were less likely to complete a scan (31 of 38 attempts; raw rate: 82%) relative to controls (73 of 75; raw rate: 96%; model-estimated difference=-14.1%, 95%CI=-27.1%; -1.1%, p=0.033). Baseline success rate was 65% (11 of 17) for ALL patients and 93% (28 of 30) for controls (model-estimated difference=-26.8%, 95%CI=-52.7%; -0.9%, p=0.42); however, nearly all T1w scans in ALL patients were successful at follow-up visits (20 of 21; 95%), with no significant differences between groups (model-estimated difference at follow-up 1=-2.1%, 95%CI=-11.7%; 7.6%; model-estimated difference at follow-up 2=-8.3%, 95%CI=-26.3%; 9.6%). A similar pattern was observed for DWI, MRS and rs-fMRI sequences with relatively high completion rates at follow-up assessments. Discussion: Non-sedated multispectral MRI is feasible in young children with newly diagnosed ALL, particularly with repeated visits and structured behavioral preparation. These results highlight opportunities to capture the scope and depth of neurodevelopmental changes concurrent with ALL treatment.
- 3 June 2025
- Published by SAGE Publications in The Cleft Palate Craniofacial Journal
- Vol. 63 (6) , 1490-1503
Associations of Sleep Disordered Breathing and Neurodevelopment with Pre-Speech Function in 2-Month-Old Infants with Oral Cleft: A Feasibility Study
Objective: Evaluate feasibility of a study to measure emergent language and pre-speech skills in infants with and without oral cleft. Functioning was assessed in relation to nighttime oxygenation and neural structure. Design: Observational, case/control study. Setting: Data was obtained at two clinical settings (University of Iowa and University of Pittsburgh Children's Hospital). Participants: Twenty infants with and without oral cleft were enrolled and evaluated at 2 months of age. Seven additional infants the same age with a subset of measures from an earlier study were also included. The combined sample included 27 participants: 5 with cleft lip only (iCL), 8 with cleft lip and palate (iCLP), and 14 unaffected (UA). Main Outcome Measures: Parent ratings of general functioning and emergent language (Bayley-4 SEABQ), acoustic measures of vocalizations, overnight pulse oximetry, and structural Magnetic resonance imaging (MRI) scans. Results: Success rates for measures were high for emergent language and vocal acoustics (100% and 89%, respectively) and moderate for oximetry and MRI scans (63% and 70%, respectively). Participants with iCLP had the lowest outcomes for emergent language and vocal acoustics, as well as the highest number of desaturations and lowest myelin intensity. Conclusions: The results of this study a ) support feasibility of obtaining pre-speech, oxygenation, and neural measures in early infancy, b ) identify patterns of higher risk for participants with iCLP, c ) and suggest that some neural differences may be present prior to exposure to anesthesia.
- 3 June 2025
- Published by SAGE Publications in The Cleft Palate Craniofacial Journal
- Vol. 63 (6) , 1490-1503
Associations of Sleep Disordered Breathing and Neurodevelopment with Pre-Speech Function in 2-Month-Old Infants with Oral Cleft: A Feasibility Study
Objective: Evaluate feasibility of a study to measure emergent language and pre-speech skills in infants with and without oral cleft. Functioning was assessed in relation to nighttime oxygenation and neural structure. Design: Observational, case/control study. Setting: Data was obtained at two clinical settings (University of Iowa and University of Pittsburgh Children's Hospital). Participants: Twenty infants with and without oral cleft were enrolled and evaluated at 2 months of age. Seven additional infants the same age with a subset of measures from an earlier study were also included. The combined sample included 27 participants: 5 with cleft lip only (iCL), 8 with cleft lip and palate (iCLP), and 14 unaffected (UA). Main Outcome Measures: Parent ratings of general functioning and emergent language (Bayley-4 SEABQ), acoustic measures of vocalizations, overnight pulse oximetry, and structural Magnetic resonance imaging (MRI) scans. Results: Success rates for measures were high for emergent language and vocal acoustics (100% and 89%, respectively) and moderate for oximetry and MRI scans (63% and 70%, respectively). Participants with iCLP had the lowest outcomes for emergent language and vocal acoustics, as well as the highest number of desaturations and lowest myelin intensity. Conclusions: The results of this study a ) support feasibility of obtaining pre-speech, oxygenation, and neural measures in early infancy, b ) identify patterns of higher risk for participants with iCLP, c ) and suggest that some neural differences may be present prior to exposure to anesthesia.
- Open Access
- 1 March 2024
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 13 (3) , 408-416
Characterization of brain development with neuroimaging in a female mouse model of chemotherapy treatment of acute lymphoblastic leukemia
Background: Survivors of pediatric acute lymphoblastic leukemia (ALL) exhibit abnormal neurocognitive outcomes that are possibly due to exposures to neurotoxic chemotherapy agents. This study aimed to determine the feasibility of characterizing long-term neuroanatomical changes with in vivo neuroimaging in a preclinical model of treatment for ALL. Methods: Female mice (C57BL/6) were randomly assigned to a saline control group (n=10) or a treatment group (n=10) that received intrathecal methotrexate and oral dexamethasone (IT-MTX + DEX). Mice were subsequently scanned three times on a 7T MRI at ages 3, 6, and 12 months (T1, T2, and T3, respectively), which corresponds with human age-equivalents spanning early to late adulthood. Regional brain volumes were automatically segmented, and volume change between timepoints (i.e., T1 to T2; and T2 to T3) were compared between groups (i.e., saline vs. IT-MTX + DEX). Results: Five mice in the IT-MTX + DEX group, and seven mice in the saline group completed all three scans. Between T1 and T2, volumetric change was significantly different between groups in total gray matter [estimate =2.06, 95% confidence interval (CI): 0.27–3.84], the cerebrum (estimate =1.62, 95% CI: 0.14–3.09), claustrum (estimate =0.06, 95% CI: 0.02–0.09), amygdala (estimate =0.16, 95% CI: 0.03–0.29), and striatum (estimate =0.18, 95% CI: 0.01–0.35), with the IT-MTX + DEX group exhibiting a more robust increase in volume than the saline-treated group. Between T2 and T3, group differences in structural brain development were evident for total white matter (estimate =−0.14, 95% CI: −0.27 to −0.01), and the corpus callosum (estimate =−0.09, 95% CI: −0.19 to 0.00) and amygdala (estimate =−0.05, 95% CI: −0.10 to 0.00). In contrast to the rapid brain growth observed earlier in development (i.e., T1 to T2), the IT-MTX + DEX group exhibited an attenuated increase in volume relative to the saline-treated group between T2 and T3. Conclusions: The results demonstrate feasibility of modeling pediatric ALL treatment in a preclinical model and highlight the potential of using preclinical neuroimaging models to gain insight into brain development throughout survivorship.
- 1 March 2024
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 13 (3) , 408-416
Open AccessCharacterization of brain development with neuroimaging in a female mouse model of chemotherapy treatment of acute lymphoblastic leukemia
Background: Survivors of pediatric acute lymphoblastic leukemia (ALL) exhibit abnormal neurocognitive outcomes that are possibly due to exposures to neurotoxic chemotherapy agents. This study aimed to determine the feasibility of characterizing long-term neuroanatomical changes with in vivo neuroimaging in a preclinical model of treatment for ALL. Methods: Female mice (C57BL/6) were randomly assigned to a saline control group (n=10) or a treatment group (n=10) that received intrathecal methotrexate and oral dexamethasone (IT-MTX + DEX). Mice were subsequently scanned three times on a 7T MRI at ages 3, 6, and 12 months (T1, T2, and T3, respectively), which corresponds with human age-equivalents spanning early to late adulthood. Regional brain volumes were automatically segmented, and volume change between timepoints (i.e., T1 to T2; and T2 to T3) were compared between groups (i.e., saline vs. IT-MTX + DEX). Results: Five mice in the IT-MTX + DEX group, and seven mice in the saline group completed all three scans. Between T1 and T2, volumetric change was significantly different between groups in total gray matter [estimate =2.06, 95% confidence interval (CI): 0.27–3.84], the cerebrum (estimate =1.62, 95% CI: 0.14–3.09), claustrum (estimate =0.06, 95% CI: 0.02–0.09), amygdala (estimate =0.16, 95% CI: 0.03–0.29), and striatum (estimate =0.18, 95% CI: 0.01–0.35), with the IT-MTX + DEX group exhibiting a more robust increase in volume than the saline-treated group. Between T2 and T3, group differences in structural brain development were evident for total white matter (estimate =−0.14, 95% CI: −0.27 to −0.01), and the corpus callosum (estimate =−0.09, 95% CI: −0.19 to 0.00) and amygdala (estimate =−0.05, 95% CI: −0.10 to 0.00). In contrast to the rapid brain growth observed earlier in development (i.e., T1 to T2), the IT-MTX + DEX group exhibited an attenuated increase in volume relative to the saline-treated group between T2 and T3. Conclusions: The results demonstrate feasibility of modeling pediatric ALL treatment in a preclinical model and highlight the potential of using preclinical neuroimaging models to gain insight into brain development throughout survivorship.
- 11 June 2023
- Published by Elsevier in Neuromuscular Disorders
- Vol. 33 (8) , 660-669
Longitudinal changes in white matter as measured with diffusion tensor imaging in adult-onset myotonic dystrophy type 1
- 11 June 2023
- Published by Elsevier in Neuromuscular Disorders
- Vol. 33 (8) , 660-669
Longitudinal changes in white matter as measured with diffusion tensor imaging in adult-onset myotonic dystrophy type 1
- Open Access
- 14 February 2022
- Published by Elsevier in Neuromuscular Disorders
- Vol. 32 (5) , 377-389
Clinical and neuroradiological correlates of sleep in myotonic dystrophy type 1
- 14 February 2022
- Published by Elsevier in Neuromuscular Disorders
- Vol. 32 (5) , 377-389
Open AccessClinical and neuroradiological correlates of sleep in myotonic dystrophy type 1
- Open Access
- 1 April 2021
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 7 (2) , e577
Neurocognitive Features of Motor Premanifest Individuals With Myotonic Dystrophy Type 1
Objective The goal of the study was to identify brain and functional features associated with premanifest phases of adult-onset myotonic dystrophy type 1 (i.e., PreDM1). Methods This cross-sectional study included 68 healthy adults (mean age = 43.4 years, SD = 12.9), 13 individuals with PreDM1 (mean age: 47.4 years, SD = 16.3), and 37 individuals with manifest DM1 (mean age = 45.2 years, SD = 9.3). The primary outcome measures included fractional anisotropy (FA), motor measures (Muscle Impairment Rating Scale, Grooved Pegboard, Finger-Tapping Test, and grip force), general cognitive abilities (Wechsler Adult Intelligence Scales), sleep quality (Scales for Outcomes in Parkinson9s Disease–Sleep), and apathy (Apathy Evaluation Scale). Results Individuals with PreDM1 exhibited an intermediate level of white matter FA abnormality, where whole-brain FA was lower relative to healthy controls (difference of the estimated marginal mean [EMMdifference] = 0.02, 95% confidence interval (CI) 0.01–0.03, p < 0.001), but the PreDM1 group had significantly higher FA than did individuals with manifest DM1 (EMMdifference = 0.02, 95% CI 0.009–0.03, p < 0.001). Individuals with PreDM1 exhibited reduced performance on the finger-tapping task relative to control peers (EMMdifference = 5.70, 95% CI 0.51–11.00, p = 0.03), but performance of the PreDM1 group was better than that of the manifest DM1 group (EMMdifference = 5.60, 95% CI 0.11–11.00, p = 0.05). Hypersomnolence in PreDM1 was intermediate between controls (EMMdifference = −1.70, 95% CI −3.10–0.35, p = 0.01) and manifest DM1 (EMMdifference = −2.10, 95% CI −3.50–0.60, p = 0.006). Conclusions Our findings highlight key CNS and functional deficits associated with PreDM1, offering insight in early disease course.
- 1 April 2021
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 7 (2) , e577
Open AccessNeurocognitive Features of Motor Premanifest Individuals With Myotonic Dystrophy Type 1
Objective The goal of the study was to identify brain and functional features associated with premanifest phases of adult-onset myotonic dystrophy type 1 (i.e., PreDM1). Methods This cross-sectional study included 68 healthy adults (mean age = 43.4 years, SD = 12.9), 13 individuals with PreDM1 (mean age: 47.4 years, SD = 16.3), and 37 individuals with manifest DM1 (mean age = 45.2 years, SD = 9.3). The primary outcome measures included fractional anisotropy (FA), motor measures (Muscle Impairment Rating Scale, Grooved Pegboard, Finger-Tapping Test, and grip force), general cognitive abilities (Wechsler Adult Intelligence Scales), sleep quality (Scales for Outcomes in Parkinson9s Disease–Sleep), and apathy (Apathy Evaluation Scale). Results Individuals with PreDM1 exhibited an intermediate level of white matter FA abnormality, where whole-brain FA was lower relative to healthy controls (difference of the estimated marginal mean [EMMdifference] = 0.02, 95% confidence interval (CI) 0.01–0.03, p < 0.001), but the PreDM1 group had significantly higher FA than did individuals with manifest DM1 (EMMdifference = 0.02, 95% CI 0.009–0.03, p < 0.001). Individuals with PreDM1 exhibited reduced performance on the finger-tapping task relative to control peers (EMMdifference = 5.70, 95% CI 0.51–11.00, p = 0.03), but performance of the PreDM1 group was better than that of the manifest DM1 group (EMMdifference = 5.60, 95% CI 0.11–11.00, p = 0.05). Hypersomnolence in PreDM1 was intermediate between controls (EMMdifference = −1.70, 95% CI −3.10–0.35, p = 0.01) and manifest DM1 (EMMdifference = −2.10, 95% CI −3.50–0.60, p = 0.006). Conclusions Our findings highlight key CNS and functional deficits associated with PreDM1, offering insight in early disease course.
- Open Access
- 1 March 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-15
White matter microstructure relates to motor outcomes in myotonic dystrophy type 1 independently of disease duration and genetic burden
Deficits in white matter (WM) integrity and motor symptoms are among the most robust and reproducible features of myotonic dystrophy type 1 (DM1). In the present study, we investigate whether WM integrity, obtained from diffusion-weighted MRI, corresponds to quantifiable motor outcomes (e.g., fine motor skills and grip strength) and patient-reported, subjective motor deficits. Critically, we explore these relationships in the context of other potentially causative variables, including: disease duration, elapsed time since motor symptom onset; and genetic burden, the number of excessive CTG repeats causing DM1. We found that fractional anisotropy (a measure of WM integrity) throughout the cerebrum was the strongest predictor of grip strength independently of disease duration and genetic burden, while radial diffusivity predicted fine motor skill (peg board performance). Axial diffusivity did not predict motor outcomes. Our results are consistent with the notion that systemic degradation of WM in DM1 mediates the relationship between DM1 progression and genetic burden with motor outcomes of the disease. Our results suggest that tracking changes in WM integrity over time may be a valuable biomarker for tracking therapeutic interventions, such as future gene therapies, for DM1.
- 1 March 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-15
Open AccessWhite matter microstructure relates to motor outcomes in myotonic dystrophy type 1 independently of disease duration and genetic burden
Deficits in white matter (WM) integrity and motor symptoms are among the most robust and reproducible features of myotonic dystrophy type 1 (DM1). In the present study, we investigate whether WM integrity, obtained from diffusion-weighted MRI, corresponds to quantifiable motor outcomes (e.g., fine motor skills and grip strength) and patient-reported, subjective motor deficits. Critically, we explore these relationships in the context of other potentially causative variables, including: disease duration, elapsed time since motor symptom onset; and genetic burden, the number of excessive CTG repeats causing DM1. We found that fractional anisotropy (a measure of WM integrity) throughout the cerebrum was the strongest predictor of grip strength independently of disease duration and genetic burden, while radial diffusivity predicted fine motor skill (peg board performance). Axial diffusivity did not predict motor outcomes. Our results are consistent with the notion that systemic degradation of WM in DM1 mediates the relationship between DM1 progression and genetic burden with motor outcomes of the disease. Our results suggest that tracking changes in WM integrity over time may be a valuable biomarker for tracking therapeutic interventions, such as future gene therapies, for DM1.
- Open Access
- 5 October 2020
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 6 (5) , e504
Variant repeats within the DMPK CTG expansion protect function in myotonic dystrophy type 1
Objective We tested the hypothesis that variant repeat interruptions (RIs) within the DMPK CTG repeat tract lead to milder symptoms compared with pure repeats (PRs) in myotonic dystrophy type 1 (DM1). Methods We evaluated motor, neurocognitive, and behavioral outcomes in a group of 6 participants with DM1 with RI compared with a case-matched sample of 12 participants with DM1 with PR and a case-matched sample of 12 unaffected healthy comparison participants (UA). Results In every measure, the RI participants were intermediate between UA and PR participants. For muscle strength, the RI group was significantly less impaired than the PR group. For measures of Full Scale IQ, depression, and sleepiness, all 3 groups were significantly different from each other with UA > RI > PR in order of impairment. The RI group was different from unaffected, but not significantly different from PR (UA > RI = PR) in apathy and working memory. Finally, in finger tapping and processing speed, RI did not differ from UA comparisons, but PR had significantly lower scores than the UA comparisons (UA = RI > PR). Conclusions Our results support the notion that patients affected by DM1 with RI demonstrate a milder phenotype with the same pattern of deficits as those with PR indicating a similar disease process.
- 5 October 2020
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 6 (5) , e504
Open AccessVariant repeats within the DMPK CTG expansion protect function in myotonic dystrophy type 1
Objective We tested the hypothesis that variant repeat interruptions (RIs) within the DMPK CTG repeat tract lead to milder symptoms compared with pure repeats (PRs) in myotonic dystrophy type 1 (DM1). Methods We evaluated motor, neurocognitive, and behavioral outcomes in a group of 6 participants with DM1 with RI compared with a case-matched sample of 12 participants with DM1 with PR and a case-matched sample of 12 unaffected healthy comparison participants (UA). Results In every measure, the RI participants were intermediate between UA and PR participants. For muscle strength, the RI group was significantly less impaired than the PR group. For measures of Full Scale IQ, depression, and sleepiness, all 3 groups were significantly different from each other with UA > RI > PR in order of impairment. The RI group was different from unaffected, but not significantly different from PR (UA > RI = PR) in apathy and working memory. Finally, in finger tapping and processing speed, RI did not differ from UA comparisons, but PR had significantly lower scores than the UA comparisons (UA = RI > PR). Conclusions Our results support the notion that patients affected by DM1 with RI demonstrate a milder phenotype with the same pattern of deficits as those with PR indicating a similar disease process.
- Open Access
- 1 July 2020
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 2 (2) , fcaa184
Brainstem and striatal volume changes are detectable in under 1 year and predict motor decline in spinocerebellar ataxia type 1
Spinocerebellar ataxia type 1 is a progressive neurodegenerative, movement disorder. With potential therapies on the horizon, it is critical to identify biomarkers that (i) differentiate between unaffected and spinocerebellar ataxia Type 1-affected individuals; (ii) track disease progression; and (iii) are directly related to clinical changes of the patient. Magnetic resonance imaging of volumetric changes in the brain may be a suitable source of biomarkers for spinocerebellar ataxia Type 1. In a previous report on a longitudinal study of patients with spinocerebellar ataxia Type 1, we evaluated the volume and magnetic resonance spectroscopy measures of the cerebellum and pons, showing pontine volume and pontine N-acetylaspartate-to-myo-inositol ratio were sensitive to change over time. As a follow-up, the current study conducts a whole brain exploration of volumetric MRI measures with the aim to identify biomarkers for spinocerebellar ataxia Type 1 progression. We adapted a joint label fusion approach using multiple, automatically generated, morphologically matched atlases to label brain regions including cerebellar sub-regions. We adjusted regional volumes by total intracranial volume allowing for linear and power-law relationships. We then utilized Bonferroni corrected linear mixed effects models to (i) determine group differences in regional brain volume and (ii) identify change within affected patients only. We then evaluated the rate of change within each brain region to identify areas that changed most rapidly. Lastly, we used a penalized, linear mixed effects model to determine the strongest brain predictors of motor outcomes. Decrease in pontine volume and accelerating decrease in putamen volume: (i) reliably differentiated spinocerebellar ataxia Type 1-affected and -unaffected individuals; (ii) were observable in affected individuals without referencing an unaffected comparison group; (iii) were detectable within ∼6–9 months; and (iv) were associated with increased disease burden. In conclusion, volumetric change in the pons and putamen may provide powerful biomarkers to track disease progression in spinocerebellar ataxia Type 1. The methods employed here are readily translatable to current clinical settings, providing a framework for study and usage of volumetric neuroimaging biomarkers for clinical trials.
- 1 July 2020
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 2 (2) , fcaa184
Open AccessBrainstem and striatal volume changes are detectable in under 1 year and predict motor decline in spinocerebellar ataxia type 1
Spinocerebellar ataxia type 1 is a progressive neurodegenerative, movement disorder. With potential therapies on the horizon, it is critical to identify biomarkers that (i) differentiate between unaffected and spinocerebellar ataxia Type 1-affected individuals; (ii) track disease progression; and (iii) are directly related to clinical changes of the patient. Magnetic resonance imaging of volumetric changes in the brain may be a suitable source of biomarkers for spinocerebellar ataxia Type 1. In a previous report on a longitudinal study of patients with spinocerebellar ataxia Type 1, we evaluated the volume and magnetic resonance spectroscopy measures of the cerebellum and pons, showing pontine volume and pontine N-acetylaspartate-to-myo-inositol ratio were sensitive to change over time. As a follow-up, the current study conducts a whole brain exploration of volumetric MRI measures with the aim to identify biomarkers for spinocerebellar ataxia Type 1 progression. We adapted a joint label fusion approach using multiple, automatically generated, morphologically matched atlases to label brain regions including cerebellar sub-regions. We adjusted regional volumes by total intracranial volume allowing for linear and power-law relationships. We then utilized Bonferroni corrected linear mixed effects models to (i) determine group differences in regional brain volume and (ii) identify change within affected patients only. We then evaluated the rate of change within each brain region to identify areas that changed most rapidly. Lastly, we used a penalized, linear mixed effects model to determine the strongest brain predictors of motor outcomes. Decrease in pontine volume and accelerating decrease in putamen volume: (i) reliably differentiated spinocerebellar ataxia Type 1-affected and -unaffected individuals; (ii) were observable in affected individuals without referencing an unaffected comparison group; (iii) were detectable within ∼6–9 months; and (iv) were associated with increased disease burden. In conclusion, volumetric change in the pons and putamen may provide powerful biomarkers to track disease progression in spinocerebellar ataxia Type 1. The methods employed here are readily translatable to current clinical settings, providing a framework for study and usage of volumetric neuroimaging biomarkers for clinical trials.
- Open Access
- 1 July 2020
- Published by Elsevier in NeuroImage
- Vol. 214, 116764
Decomposing the neural pathways in a simple, value-based choice
- 1 July 2020
- Published by Elsevier in NeuroImage
- Vol. 214, 116764
Open AccessDecomposing the neural pathways in a simple, value-based choice